Literature DB >> 12170765

Differential inactivation of caspase-8 in lung cancers.

Narayan Shivapurkar1, Shinichi Toyooka, Michael T Eby, Chun Xian Huang, Ubaradka G Sathyanarayana, H Thomas Cunningham, Jyotsna L Reddy, Elizabeth Brambilla, Takashi Takahashi, John D Minna, Preet M Chaudhary, Adi F Gazdar.   

Abstract

Caspase-8 (CASP8) is an apoptosis inducing cysteine protease which is activated through the formation of a death-inducing signaling complex when death receptors are complexed to their specific ligands. Recent reports indicate that CASP8 expression is lost via a combination of promoter methylation and allelic loss in subset of neuroblastomas. We investigated the state of the gene in lung tumors and cell lines. RT-PCR studies indicated that gene expression was lost in most (27 of 34, 79%) of small cell lung carcinoma (SCLC) cell lines, but expression was retained in all 22 non-SCLC (NSCLC) lines tested. Loss of gene expression at the RNA level was associated with absent protein expression by Western blotting and lack of CASP8 enzymatic activity. Methylation of the promoter region of the CASP8 gene was present in 16 of 27 (59%) of the SCLC lines lacking gene expression. All methylated cell lines lacked the presence of an unmethylated allele indicating biallelic methylation or loss of non-methylated allele. Promoter methylation was absent in all SCLC and NSCLC cell lines retaining gene expression, and all of these lines had the unmethylated form of the gene. One non-expressing SCLC cell line, NCI-H82, had a homozygous deletion at 2q33 encompassing the chromosomal location of the CASP8 gene. The mechanism of gene inactivation in the remaining 10 of 27 (37%) non-expressing SCLC cell lines is unknown. Using five polymorphic markers for 2q33 a high frequency of allelic loss was present in SCLC lines. Analyses of fresh tumors showed that 15 of 43 (35%) of the SCLC, seven of 40 (18%) of bronchial carcinoids and none of 44 NSCLC tumors had CASP8 promoter methylation. Because only approximately 60% of SCLC cell lines lacking CASP8 expression were methylated, extrapolating from the cell line data, we estimate that approximately 58% of SCLC and 30% of bronchial carcinoids lack CASP8 expression. Thus, CASP8 expression is absent in a subset of both high grade (SCLC) and low grade (carcinoid) neuroendocrine lung tumors but not in NSCLC, which usually lack neuroendocrine features. CASP8 may function as a tumor suppressor gene in neuroendocrine lung tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170765     DOI: 10.4161/cbt.1.1.45

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  42 in total

Review 1.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Authors:  Adi F Gazdar; Boning Gao; John D Minna
Journal:  Lung Cancer       Date:  2010-01-15       Impact factor: 5.705

Review 2.  Caspase-8 as a therapeutic target in cancer.

Authors:  Dwayne G Stupack
Journal:  Cancer Lett       Date:  2010-09-03       Impact factor: 8.679

3.  Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells.

Authors:  Manrong Jiang; Kejin Zhu; Jose Grenet; Jill M Lahti
Journal:  Biochim Biophys Acta       Date:  2008-03-10

4.  Mathematical modelling of cell-fate decision in response to death receptor engagement.

Authors:  Laurence Calzone; Laurent Tournier; Simon Fourquet; Denis Thieffry; Boris Zhivotovsky; Emmanuel Barillot; Andrei Zinovyev
Journal:  PLoS Comput Biol       Date:  2010-03-05       Impact factor: 4.475

5.  A new caspase-8 isoform caspase-8s increased sensitivity to apoptosis in Jurkat cells.

Authors:  Zhifang Xu; Kejing Tang; Min Wang; Qing Rao; Bolin Liu; Jianxiang Wang
Journal:  J Biomed Biotechnol       Date:  2010-01-27

6.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

7.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

8.  Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.

Authors:  Kyung Hwa Lee; Sang Woo Lim; Ho Gun Kim; Dong Yi Kim; Seong Yeob Ryu; Jae Kyun Joo; Jung Chul Kim; Jae Hyuk Lee
Journal:  Langenbecks Arch Surg       Date:  2009-04-07       Impact factor: 3.445

Review 9.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 10.  Epigenetics in non-small cell lung cancer: from basics to therapeutics.

Authors:  Junaid Ansari; Rodney E Shackelford; Hazem El-Osta
Journal:  Transl Lung Cancer Res       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.